Why it matters
The findings may inform future treatment options for people with nonsegmental vitiligo. The report does not say that povorcitinib is approved for this condition or establish when it might become available.
RESEARCH & TREATMENTS • UNITED STATES
Phase 3 trials find povorcitinib improved vitiligo measure versus placebo
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
This event has left the current brief. The summary below describes the stored record; open the original sources for current conditions.
BLUF
Two randomized, controlled phase 3 trials found that povorcitinib, an oral JAK1 inhibitor, outperformed placebo on an F-VASI75 improvement measure in people with nonsegmental vitiligo. The supplied report does not give effect sizes, safety details or regulatory status.
HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections